Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Roche, Curis Drug Prevented Lesions, Reduced Tumor Size in Trial

April 1 (Bloomberg) -- Roche Holding AG and Curis Inc.’s experimental drug shrank tumors and prevented new lesions in a clinical trial of skin-cancer patients with a rare inheritable disease.

Patients given the medicine, known as vismodegib or GDC-0449, had fewer basal cell carcinomas than those who received a placebo, according to a statement from the American Association for Cancer Research conference in Orlando, Florida. The size of existing tumors “decreased significantly” for those getting the drug, while carcinomas were “essentially unchanged” for patients who got placebo, researchers said.

The 41 patients in the trial had basal cell nevus syndrome, a disease that leads to a higher risk of skin cancers. Side effects, including loss of taste, muscle cramps and weight loss, caused 20 percent of patients to discontinue the drug.

To contact the reporter on this story: Phil Serafino in Paris at pserafino@bloomberg.net.

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.